Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes

Jung S, Bosch A, Kannenkeril D, Karg MV, Striepe K, Bramlage P, Ott C, Schmieder R, Jung S (2020)

Publication Type: Journal article

Publication year: 2020

Journal

European Heart Journal - Cardiovascular Pharmacotherapy Oxford University Press

Book Volume: 6

Pages Range: 364-371

Journal Issue: 6

DOI: 10.1093/ehjcvp/pvz078

Abstract

AIMS: Preserved vascular function represents a key prognostic factor in type 2 diabetes mellitus (T2DM), but data on vascular parameters in this patient cohort are scarce. Patients with T2DM often need more than one drug to achieve optimal glucose control. The aim of this study was to analyse the efficacy of two combination therapies on vascular function in subjects with T2DM. METHODS AND RESULTS: This prospective, randomized study included 97 subjects with T2DM. Subjects were randomized to either the combination therapy empagliflozin (E) 10 mg with linagliptin (L) 5 mg once daily or metformin (M) 850 or 1000 mg twice daily with insulin glargine (I) once daily. At baseline and after 12 weeks, subjects had peripheral office and 24-h ambulatory blood pressure (BP) measurement and underwent vascular assessment by pulse wave analysis under office and ambulatory conditions. Office, 24-h ambulatory and central BP as well as pulse pressure (PP) decreased after 12 weeks of treatment with E + L, whereas no change was observed in M + I. There were greater decreases in 24-h ambulatory peripheral systolic (between-group difference: -5.2 ± 1.5 mmHg, P = 0.004), diastolic BP (-1.9 ± 1.0 mmHg, P = 0.036), and PP (-3.3 ± 1.0 mmHg, P = 0.007) in E + L than M + I. Central office systolic BP (-5.56 ± 1.9 mmHg, P = 0.009), forward pressure height of the pulse wave (-2.0 ± 0.9 mmHg, P = 0.028), 24-h ambulatory central systolic (-3.6 ± 1.4 mmHg, P = 0.045), diastolic BP (-1.95 ± 1.1 mmHg, P = 0.041), and 24-h pulse wave velocity (-0.14 ± 0.05m/s, P = 0.043) were reduced to a greater extent with E + L. CONCLUSION: Beyond the effects on glycaemic control, the combination therapy of E + L significantly improved central BP and vascular function compared with the classic combination of M + I. CLINICALTRIALS.GOV: NCT02752113.

Authors with CRIS profile

Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Kristina Striepe Professur für Innere Medizin (Nephrologie) Christian Ott Department of Medicine 4 – Nephrology and Hypertension Roland Schmieder Professur für Innere Medizin (Nephrologie) Susanne Jung Professur für Innere Medizin (Nephrologie)

Involved external institutions

IPPMed - Institut für Pharmakologie und Präventive Medizin GmbH DE Germany (DE)

How to cite

APA:

Jung, S., Bosch, A., Kannenkeril, D., Karg, M.V., Striepe, K., Bramlage, P.,... Jung, S. (2020). Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 6(6), 364-371. https://doi.org/10.1093/ehjcvp/pvz078

MLA:

Jung, Susanne, et al. "Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes." European Heart Journal - Cardiovascular Pharmacotherapy 6.6 (2020): 364-371.

BibTeX: Download